Jacob Asset Management of New York’s CRISPR Therapeutics CRSP Stock Holding History

Jacob Asset Management of New York’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$182K	Buy	4,003 +390	+11%	+$20.1K	0.26%	57
2023 Q2	$203K	Sell	3,613 -7	-0.2%	-$397	0.23%	59
2023 Q1	$164K	Buy	3,620 +330	+10%	+$16K	0.19%	59
2022 Q4	$134K	Buy	3,290 +648	+25%	+$34.4K	0.16%	62
2022 Q3	$173K	Sell	2,642 -256	-9%	-$18.6K	0.19%	61
2022 Q2	$176K	Hold	2,898	–	–	0.18%	65
2022 Q1	$182K	Sell	2,898 -4	-0.1%	-$251	0.11%	67
2021 Q4	$220K	Buy	2,902 +2,329	+406%	+$203K	0.1%	73
2021 Q3	$64K	Buy	+573	New	+$72K	0.02%	79

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jacob Asset Management of New York's CRSP Position: Q3 2023 in Review

Jacob Asset Management of New York increased its CRISPR Therapeutics (CRSP) stake by 11% in Q3 2023, buying an estimated $20.1K and bringing the position to 4,003 shares worth $182K. The position accounts for 0.26% of the portfolio, ranked #57.

Jacob Asset Management of New York first reported a position in CRSP in Q3 2021 and has held it in 9 quarters since. The position peaked at $220K in Q4 2021. 406 funds tracked by Wall St. Rank hold CRSP as of Q3 2023.

Jacob Asset Management of New York held 4,003 shares of CRISPR Therapeutics worth $182K as of Q3 2023.
Jacob Asset Management of New York bought 390 CRISPR Therapeutics shares in Q3 2023, an estimated $20.1K.
CRISPR Therapeutics made up 0.26% of Jacob Asset Management of New York's portfolio in Q3 2023, its #57 holding.
Jacob Asset Management of New York first reported a position in CRISPR Therapeutics in Q3 2021 and has held it in 9 quarters since.
Jacob Asset Management of New York's CRISPR Therapeutics position peaked at $220K in Q4 2021.
406 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2023.

Based on Jacob Asset Management of New York's 13F filing for Q3 2023, filed 1 Nov 2023.